CA2190679A1 - Tachykinine lymphocytaire - Google Patents

Tachykinine lymphocytaire

Info

Publication number: CA2190679A1
Authority: CA; Canada
Prior art keywords: substance; cells; ppt; peptide; gene
Prior art date: 1996-11-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2190679

Other languages

English (en)

Inventor

Christopher J. Paige

Gillian E. Wu

Yu Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Wellesley Hospital Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-19

Filing date

1996-11-19

Publication date

1998-05-19

1996-11-19 Application filed by Wellesley Hospital Foundation filed Critical Wellesley Hospital Foundation

1996-11-19 Priority to CA 2190679 priority Critical patent/CA2190679A1/fr

1997-11-19 Priority to PCT/CA1997/000875 priority patent/WO1998022497A1/fr

1997-11-19 Priority to AU50446/98A priority patent/AU5044698A/en

1997-11-19 Priority to EP97913048A priority patent/EP0941234A1/fr

1997-11-19 Priority to CA002271714A priority patent/CA2271714A1/fr

1998-05-19 Publication of CA2190679A1 publication Critical patent/CA2190679A1/fr

Status Abandoned legal-status Critical Current

Links

108060008037 tachykinin Proteins 0.000 title description 19
102000003141 Tachykinin Human genes 0.000 title description 16
210000004698 lymphocyte Anatomy 0.000 title description 2
239000000126 substance Substances 0.000 description 123
210000004027 cell Anatomy 0.000 description 65
108090000765 processed proteins & peptides Proteins 0.000 description 48
101710149435 Tachykinin-4 Proteins 0.000 description 35
238000000034 method Methods 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 29
210000001519 tissue Anatomy 0.000 description 26
239000002299 complementary DNA Substances 0.000 description 23
102000004196 processed proteins & peptides Human genes 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 21
102100039365 Tachykinin-4 Human genes 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
230000000694 effects Effects 0.000 description 17
210000002950 fibroblast Anatomy 0.000 description 17
241001465754 Metazoa Species 0.000 description 16
239000005557 antagonist Substances 0.000 description 16
210000000845 cartilage Anatomy 0.000 description 16
102100024304 Protachykinin-1 Human genes 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
230000014509 gene expression Effects 0.000 description 14
239000002243 precursor Substances 0.000 description 14
150000007523 nucleic acids Chemical class 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
108020004414 DNA Proteins 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
238000003776 cleavage reaction Methods 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
230000007017 scission Effects 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
238000003556 assay Methods 0.000 description 10
210000003630 histaminocyte Anatomy 0.000 description 10
239000000523 sample Substances 0.000 description 10
238000012216 screening Methods 0.000 description 10
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 9
101800003906 Substance P Proteins 0.000 description 9
239000002609 medium Substances 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 8
238000010171 animal model Methods 0.000 description 8
230000027455 binding Effects 0.000 description 8
239000003636 conditioned culture medium Substances 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000012634 fragment Substances 0.000 description 8
230000012010 growth Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
101800000399 Neurokinin A Proteins 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
108091034057 RNA (poly(A)) Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
108700019146 Transgenes Proteins 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
230000001605 fetal effect Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
241001529936 Murinae Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000008355 cartilage degradation Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
238000009472 formulation Methods 0.000 description 5
210000005229 liver cell Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
229940076279 serotonin Drugs 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
108010002586 Interleukin-7 Proteins 0.000 description 4
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 4
101800002813 Neurokinin-B Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
102100033009 Tachykinin-3 Human genes 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000008272 agar Substances 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
210000000287 oocyte Anatomy 0.000 description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
239000013598 vector Substances 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000012258 culturing Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 3
239000007758 minimum essential medium Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
210000001948 pro-b lymphocyte Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000001626 skin fibroblast Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
SHSUJLMLURFKID-YFUSJSQUSA-N (3s)-4-[(2s)-2-[[(2s)-4-amino-1-[[(2s)-6-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 SHSUJLMLURFKID-YFUSJSQUSA-N 0.000 description 2
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 2
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
241000714175 Abelson murine leukemia virus Species 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
108010051021 Eledoisin Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
108010025252 Kassinin Proteins 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
102400000097 Neurokinin A Human genes 0.000 description 2
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108010007301 Physalaemin Proteins 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000005546 dideoxynucleotide Substances 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
AYLPVIWBPZMVSH-FCKMLYJASA-N eledoisin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 AYLPVIWBPZMVSH-FCKMLYJASA-N 0.000 description 2
229950011049 eledoisin Drugs 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
230000000925 erythroid effect Effects 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
210000003297 immature b lymphocyte Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
GDBREXONAMPGBA-FJCMUPJRSA-N kassinin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=CC=C1 GDBREXONAMPGBA-FJCMUPJRSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
-1 neurokinin a Chemical compound 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108010030540 protachykinin Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
210000005222 synovial tissue Anatomy 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
NQEQTYPJSIEPHW-UHFFFAOYSA-N 1-C-(indol-3-yl)glycerol 3-phosphate Chemical compound C1=CC=C2C(C(O)C(COP(O)(O)=O)O)=CNC2=C1 NQEQTYPJSIEPHW-UHFFFAOYSA-N 0.000 description 1
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000006822 Agouti Signaling Protein Human genes 0.000 description 1
108010072151 Agouti Signaling Protein Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
101100247440 Arabidopsis thaliana RBL5 gene Proteins 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000484025 Cuniculus Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 description 1
101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
108010063678 Indole-3-Glycerol-Phosphate Synthase Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
101000655187 Mus musculus Tachykinin-3 Proteins 0.000 description 1
101000669527 Mus musculus Tachykinin-4 Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000046798 Neurokinin B Human genes 0.000 description 1
101000879596 Nicotiana tabacum Acidic endochitinase P Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000004107 Penicillin G sodium Substances 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
241000219061 Rheum Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 description 1
102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
101150050280 alsD gene Proteins 0.000 description 1
QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
108010052590 amastatin Proteins 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940093740 amino acid and derivative Drugs 0.000 description 1
LDPIQRWHBLWKPR-UHFFFAOYSA-N aminoboronic acid Chemical compound NB(O)O LDPIQRWHBLWKPR-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000012435 analytical chromatography Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000011882 arthroplasty Methods 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000021235 carbamoylation Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000007799 cork Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229940119743 dextran 70 Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
108010042617 dinitrophenyl-human serum albumin conjugate Proteins 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000002980 germ line cell Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
238000013150 knee replacement Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000019369 penicillin G sodium Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
108010041634 preprotachykinin Proteins 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
101150044170 trpE gene Proteins 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Life Sciences & Earth Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2190679 1996-11-19 1996-11-19 Tachykinine lymphocytaire Abandoned CA2190679A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
CA 2190679 CA2190679A1 (fr)	1996-11-19	1996-11-19	Tachykinine lymphocytaire
PCT/CA1997/000875 WO1998022497A1 (fr)	1996-11-19	1997-11-19	Gene de la preprotachykinine-c codant le precurseur d'une tachykinine denommee substance z
AU50446/98A AU5044698A (en)	1996-11-19	1997-11-19	Preprotachykinin-c gene encoding substance z tachykinin precursor
EP97913048A EP0941234A1 (fr)	1996-11-19	1997-11-19	Gene de la preprotachykinine-c codant le precurseur d'une tachykinine denommee substance z
CA002271714A CA2271714A1 (fr)	1996-11-19	1997-11-19	Gene de la preprotachykinine-c codant le precurseur d'une tachykinine denommee substance z

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2190679 CA2190679A1 (fr)	1996-11-19	1996-11-19	Tachykinine lymphocytaire

Publications (1)

Publication Number	Publication Date
CA2190679A1 true CA2190679A1 (fr)	1998-05-19

Family

ID=4159280

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2190679 Abandoned CA2190679A1 (fr)	1996-11-19	1996-11-19	Tachykinine lymphocytaire

Country Status (4)

Country	Link
EP (1)	EP0941234A1 (fr)
AU (1)	AU5044698A (fr)
CA (1)	CA2190679A1 (fr)
WO (1)	WO1998022497A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4166408B2 (ja) *	1999-07-30	2008-10-15	サントリー株式会社	新規タキキニンペプチドおよびその前駆体ポリペプチドならびにこれらをコードする遺伝子
US7235531B2 (en)	1999-12-21	2007-06-26	Takeda Pharmaceutical Company	Tachykinin-like polypeptides and use thereof
WO2005103712A2 (fr) *	2004-04-20	2005-11-03	Sphingotec Gmbh	Utilisation de precurseurs de tachykinines et/ou de fragments de celles-ci dans un diagnostic medical

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8613431D0 (en) *	1986-06-03	1986-07-09	Medical Res Council	Human tachykinins
ATE186550T1 (de) *	1991-04-22	1999-11-15	Mallinckrodt Medical Inc	Verbindungen und pharmazeutische zusammensetzungen zum nachweis und zur lokalisierung von geweben mit neurokinin-1- rezeptoren

1996
- 1996-11-19 CA CA 2190679 patent/CA2190679A1/fr not_active Abandoned
1997
- 1997-11-19 WO PCT/CA1997/000875 patent/WO1998022497A1/fr not_active Ceased
- 1997-11-19 AU AU50446/98A patent/AU5044698A/en not_active Abandoned
- 1997-11-19 EP EP97913048A patent/EP0941234A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
WO1998022497A1 (fr)	1998-05-28
AU5044698A (en)	1998-06-10
EP0941234A1 (fr)	1999-09-15

Publication	Publication Date	Title
US7314621B2 (en)	2008-01-01	Cytidine deaminase
Berman et al.	1987	Sequence analysis, cellular localization, and expression of a neuroretina adhesion and cell survival molecule
JP4689781B2 (ja)	2011-05-25	アミノ酸輸送蛋白及びその遺伝子
FI106044B (fi)	2000-11-15	Menetelmä nisäkkään interleukiini-4-reseptorin (IL-4R) ja sen vasta-aineen tuottamiseksi ja IL-4R:ä koodaava DNA, vektori ja isäntäsolu
US5455337A (en)	1995-10-03	DNA encoding chimeric polypeptides comprising the interleukin-5 receptor α-chain fused to immunoglobulin heavy chain constant regions
PT1009832E (pt)	2007-01-31	Citoquina designada lerk-6
JPH07509370A (ja)	1995-10-19	ウイルスタンパク質の発現を増大する方法
JPH08510897A (ja)	1996-11-19	細胞外シグナル制御キナーゼ、配列、製造法および用途
US6174703B1 (en)	2001-01-16	Genes encoding telomerase protein 1
JP2001523977A (ja)	2001-11-27	Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
US5866372A (en)	1999-02-02	Nucleic acids encoding lymphoid CD30 antigen
JPH06501381A (ja)	1994-02-17	ヒトマクロファージ炎症性タンパク質２α
US5885797A (en)	1999-03-23	Polynucleotide sequences encoding proteins involved in myogenesis
WO1998057984A2 (fr)	1998-12-23	Torsine, genes de torsine et leurs utilisations
CA2190679A1 (fr)	1998-05-19	Tachykinine lymphocytaire
WO1998038302A2 (fr)	1998-09-03	Sous-unite alpha de canal sodique sensible a la tetrodotoxine
Magyar et al.	1995	Structure and tissue-specific expression of the Drosophila melanogaster organellar-type Ca2+-ATPase gene
JPH07506007A (ja)	1995-07-06	Ｉｃａｍ−関連タンパク質
CA2490051A1 (fr)	2003-12-11	Nouvelles sequences gdf-9 et gdf-9b (bmp-15) destinees a modifier la fonction ovarienne et la vitesse d'ovulation chez des mammiferes
DE69434090T2 (de)	2006-03-09	Epsilon-untereinheit des gaba a-rezeptors
US5866123A (en)	1999-02-02	Gene encoding cationic amino acid transporter protein
JP4750222B2 (ja)	2011-08-17	アミノ酸輸送蛋白及びその遺伝子
JPH06211898A (ja)	1994-08-02	神経α−カテニン
CA2271714A1 (fr)	1998-05-28	Gene de la preprotachykinine-c codant le precurseur d'une tachykinine denommee substance z
DE69637429T2 (de)	2009-07-09	Gene, die für lymphocyte spezifischen interferon-regulationsfaktor (lsirf) polypeptide kodiert

Legal Events

Date	Code	Title	Description
1999-07-07	FZDE	Dead